Medartis Shareholders Approve All Board Proposals at 2026 AGM with Strong Support

Medartis Holding AG (SIX: MED) announced that its shareholders approved all substantive proposals of the Board of Directors with significant majorities exceeding 90.9% at the 2026 Annual General Meeting (AGM) held on April 23, 2026, at the company's headquarters in Basel, Switzerland. The meeting saw strong participation, with 10,545,669 shares represented, constituting 77.4% of total share capital.

All seven incumbent board members standing for re-election received resounding endorsement, each securing more than 93.8% support from represented votes. Yang Xu was newly elected to the Board of Directors with 99.7% endorsement and will join the Finance and Audit Committee. Chairman Marco Gadola will continue to lead the board. After two years with Medartis, Jennifer Dean decided not to stand for re-election. The assembly also confirmed Damien Tappy and Marco Gadola as members of the Human Resources and Compensation Committee, ensuring continuity in oversight of the company's human capital strategy.

Shareholders granted discharge to board members for their governance during the 2025 term. The proposed maximum total remuneration for both the Board of Directors and the Executive Management Board, including fixed and variable components, was approved through separate votes. The 2025 management report and annual financial statements received nearly unanimous approval (99.99%), while the remuneration report was approved by 91.0% in a consultative vote. Additionally, the sustainability report gained strong endorsement with 99.2% of represented shares, confirming Medartis' commitment to transparent ESG practices.

The AGM also confirmed the re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors. For a detailed listing of all resolutions at the 2026 Annual General Meeting, please visit this link.

Medartis also confirmed upcoming dates for its investor and corporate calendar. On June 4, 2026, Medartis will host an investor event in Basel, held on the fringes of the FESSH Hand Surgery Congress. The first-half 2026 results will be published on August 18, 2026, followed by the customary analyst and media briefing. The next Annual General Meeting is scheduled for April 22, 2027, at the company's headquarters in Basel.

The strong shareholder support underscores confidence in Medartis' strategic direction and governance. As of the AGM, the Medartis Board of Directors consists of Marco Gadola (Chairman), Dr. h.c. Thomas Straumann (Vice Chairman), Willi Miesch, Damien Tappy, Nadia Tarolli Schmidt, Ciro Roemer, Martha Shadan, and Yang Xu. For more information about Medartis, visit www.medartis.com.